Bird & Bird advises AddLife on the acquisition of Ropox A/S
The Swedish listed company AddLife AB is a market leading player within Life Science offering quality products and advice to both the private and the public sectors, primarily in the Nordics and the rest of Europe.
The Swedish listed company AddLife AB is a market leading player within Life Science offering quality products and advice to both the private and the public sectors, primarily in the Nordics and the rest of Europe.
Bird & Bird has advised AddLife on the acquisition of Ropox A/S, a market leader among the world’s leading specialists within the production of assistive devices and furniture for disabled persons and equipment for rehabilitation by means of occupational therapy and physiotherapy. The Ropox premises are located in Næstved with 73 employees and an annual turnover of approximately DKK 65 million.
AddLife has purchased all the shares with effect from 1 October 2020. The purchase price is confidential.
AddLife’s press release on the acquisition can be found here.
AddLife was advised by senior counsel Mogens Dyhr Vestergaard, senior associate Ted Rosenbaum and junior associate Filip Kaas.
